Skip to main content

Macular Degeneration clinical trials at UC Irvine
4 in progress, 2 open to eligible people

  • Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

    open to eligible people ages 55 years and up

    The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).

    Irvine, California and other locations

  • Telescope Exchange Study

    open to eligible people ages 65 years and up

    VisionCare's Implantable Miniature Telescope (IMT, intraocular telescope or telescope) is indicated for monocular implantation to improve vision in eyes of patients at least 65 years of age with severe to profound vision impairment caused by bilateral central scotomas associated with end-stage age-related macular degeneration (AMD). Patients with end-stage AMD who have undergone bilateral cataract removal and intraocular lens placement are currently contraindicated for telescope surgery. These patients have no viable therapy available to improve their vision. The objective of the TES pilot study is to evaluate the safety and effectiveness of implanting the intraocular telescope for improving vision in patients with bilateral end-stage age- related macular degeneration who are pseudophakic.

    Irvine, California and other locations

  • Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

    Sorry, in progress, not accepting new patients

    This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration.

    Irvine, California and other locations

  • Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

    Sorry, not currently recruiting here

    This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.

    Irvine, California and other locations

Last updated: